Sanofi turns to G-BA for Jevtana benefits decision after vague IQWiG's assessment
25 January 2012
Francesca Bruce
Please Login to read the full article.
25 January 2012
Francesca Bruce
Please Login to read the full article.
RELATED CONTENT
NEWS
- NICE U-turn puts Janssen's Zytiga ahead of Sanofi's Jevtana in prostate cancer
- SMC vetoes Sanofi's Jevtana, AZ's Vimovo and Merck's Emend, but OKs Simponi again
- Janssen's Zytiga fails to impress NICE
- Sanofi's Jevtana still too expensive for NICE, despite end-of-life credentials rethink
ANALYSIS
Other Informa Analysis
COMMENT
Other Informa Comment
EVENTS
Today
The Rembrandt Hotel, London
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
